Completed NA INTERVENTIONAL 2-arm NCT01312831

Efficacy and Safety Study of Oral Eligen® B12 in Subjects With Low Serum Cobalamin

A 60-DAY, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Eligen® B12 OR Intramuscularly Administered B12 in Subjects With Low Serum Cobalamin With a 30 Day Extension to 90 Days of Dosing

Sponsor: Emisphere Technologies, Inc.

Conditions Vitamin B 12 Deficiency

Interventions Vitamin B12 (cyanocobalamin)

Updated 5 times since 2017 Last updated: Mar 9, 2011 Started: Feb 28, 2009 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Vitamin B 12 Deficiency, this trial is completed. The trial is conducted by Emisphere Technologies, Inc. and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emisphere Technologies, Inc.

Data source: Emisphere Technologies, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.